Ab (1-40) together with Ab (1-42) are two major C-terminal variants of the Ab protein constituting the majority of Abs. These undergo post-secretory aggregation and deposition in the Alzheimer’s disease brain.
This cGMP beta-Amyloid 1-40 peptide has been produced under conditions compliant with 21 CFR part 820 & ISO 13485 and is appropriate for use as an IVD component or as a quality control standard (not for human use).
Peptide Purity: =95%
Endotoxin: =1 EU/mg
Bioburden: Report Results (Lot specific)
Solubility: Report Results (Lot specific)
Monomer content: Report Results (Lot specific)